Patent expiry for alirocumab is not a single date. It varies by country and by patent family (composition of matter, use, formulation, etc.), and can also be affected by patent term adjustments and regulatory exclusivities for biologics.
If you can tell me:
- which country or region you care about (e.g., US, EU, UK, India, etc.), and
- whether you want the status of the core composition-of-matter patents, method‑of‑use patents, or regulatory exclusivity,
I can give you a country-specific summary with approximate expiry windows and references.
A few important notes:
- In biologics like alirocumab, even after patents expire, there can be additional protection from regulatory data exclusivity (e.g., in the US, the BPCIA provides data exclusivity for biologics for a set period), which can delay biosimilar entry.
- Real dates are all over the place because of different patent families and term extensions, so a jurisdiction-by-jurisdiction check is the safest approach.
If you’d like, I can outline a quick way to look this up in public patent databases (USPTO, Espacenet, Google Patents) and point you to the key assignees (Regeneron, Sanofi) and likely patent families to review.